Novacyt S.A. Conversion of Loan Notes (7403F)
16 Julio 2019 - 10:30AM
UK Regulatory
TIDMNCYT
RNS Number : 7403F
Novacyt S.A.
16 July 2019
Novacyt S.A.
("Novacyt" or the "Company")
Conversion of Loan Notes
Paris, France and Camberley, UK - 16 July 2019 - Novacyt
(EURONEXT GROWTH: ALNOV; AIM: NCYT) an international specialist in
clinical diagnostics, announces that, pursuant to the Convertible
Bonds with Warrants Funding Programme announced on 23 April 2019,
it has issued a tranche of new ordinary shares of EUR1/15 each
("Ordinary Shares") to Negma Group Limited following the receipt of
conversion notices. Further details are set out below.
Conversion notices dated: 15 July 2019
Number of Notes converted 30
Conversion amount EUR75,000
Lowest VWAP during the 15 days preceding
the conversion notice EUR0.0875
Conversion price EUR0.07
Number of shares issued 1,071,428
Application will be made for the 1,071,428 new Ordinary Shares
to be admitted to trading on AIM ("Admission") and it is expected
that Admission will occur on 22 July 2019. Admission of the new
Ordinary Shares to trading on Euronext is expected to occur on or
before 22 July 2019.
Total Voting Rights
Following Admission, the total number of ordinary shares in the
Company is 41,756,945. This figure may be used by shareholders as
the denominator for calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the Company pursuant to Article L. 223-7 of the French
Commercial Code and the Company's Articles. The Company is not
subject to the disclosure guidance and transparency rules made by
the Financial Conduct Authority under Part VI of FSMA.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
- End -
For further information, please refer to www.novacyt.com or
contact:
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1223 395472
SP Angel Corporate Finance LLP (Nominated Adviser and Joint
Broker)
Matthew Johnson / Jamie Spotswood (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
WG Partners (Joint Broker)
Nigel Birks / Chris Lee / Claes Spång
+44 (0) 203 705 9330
FTI Consulting (International)
Brett Pollard / Victoria Foster Mitchell/ Mary Whittow
+44 (0)20 3727 1000
brett.pollard@fticonsulting.com/victoria.fostermitchell@fticonsulting.com/
Mary.whittow@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines / Astrid Villette
+33 (0)147 03 69 47 / +33 (0)147 03 69 51
arnaud.decheffontaines@fticonsulting.com /
astrid.villette@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company's lead business units comprise of Primerdesign and
Lab21 Products, supplying an extensive range of high quality assays
and reagents worldwide. The Group directly serves oncology,
microbiology, haematology and serology markets as do its global
partners, which include major corporates.
For more information please refer to the website:
www.novacyt.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCBUGDRIDBBGCL
(END) Dow Jones Newswires
July 16, 2019 11:30 ET (15:30 GMT)
Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Novacyt (LSE:NCYT)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024